bioRxiv · 10.64898/2026.09.21.753226
Discovery and Optimization of Imidazothiazole Carboxamides as Novel Anti-Tuberculosis Agents
Abstract
Screening of the open-access CRESTdb small-molecule library identified the imidazothiazole carboxamide sCQG200 (1) as an initial hit, with activity against H37Rv and Erdman Mycobacterium tuberculosis strains in cholesterol-containing medium (MIC90= 6.88 uM and 4.48 uM, respectively) and against intracellular Mtb (EC50= 3.80 uM). sCQG200 retained activity against drug-resistant Mtb strains, including clinical MDR/XDR isolates. SAR optimization led to analogs 21 and 24 with substantially improved antimycobacterial potency. Mouse pharmacokinetic studies following oral and intravenous administration showed 62.1% and 29.5% oral bioavailability for 21 and 24, respectively. This structurally differentiated chemotype provides a promising starting point for further optimization as antitubercular agent.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Meng, L., Grant, D., Xie, H., Ford, R., Webb, J., McNamara, C. W., Sukheja, P., Yang, B., Chatterjee, A. K.. 2026-09-24. Discovery and Optimization of Imidazothiazole Carboxamides as Novel Anti-Tuberculosis Agents. https://doi.org/10.64898/2026.09.21.753226
Cite the original work for its findings. Save a collection to share your selection of sources.